Incremental Impact of [68 Ga]Ga-PSMA-11 PET/CT in Primary N and M Staging of Prostate Cancer Prior to Curative-Intent Surgery: a Prospective Clinical Trial in Comparison with mpMRI.
Florian SzigetiGregor Schweighofer-ZwinkMatthias MeissnitzerCornelia Hauser-KronbergerWolfgang HitzlThomas KunitRosemarie ForstnerChristian PirichMohsen BeheshtiPublished in: Molecular imaging and biology (2021)
[68 Ga]Ga-PSMA-11 PET/CT shows high diagnostic performance for N and M staging of patients with intermediate- and high-risk prostate cancer and seems to be superior to pelvic mpMRI in the detection of locoregional lymph node metastases. A significant correlation was found between SUVmax of the intraprostatic index lesion and risk stratification based on tPSA level and GS. The results of this study emphasize again on the role of metabolic molecular imaging using specific tracers in selected patients, leading to tailored therapy approach.
Keyphrases
- pet ct
- prostate cancer
- lymph node
- clinical trial
- radical prostatectomy
- end stage renal disease
- positron emission tomography
- prognostic factors
- ejection fraction
- chronic kidney disease
- minimally invasive
- rectal cancer
- newly diagnosed
- peritoneal dialysis
- randomized controlled trial
- stem cells
- neoadjuvant chemotherapy
- coronary artery disease
- cell therapy
- phase ii
- acute coronary syndrome
- early stage
- double blind
- percutaneous coronary intervention